Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Blinatumomab (Blincyto) for Minimal Residual Disease Positive B-cell Precursor Acute Lymphoblastic Leukemia
(Open for Input on Submission until February 3, 2020)

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer
(Final Recommendation Issued as of January 22, 2020)

Cemiplimab (Libtayo) for Advanced Cutaneous Squamous Cell Carcinoma
(Final Recommendation Issued as of January 22, 2020)

Pembrolizumab (Keytruda) for Squamous Non-Small Cell Lung Cancer
(Notification to Implement Issued as of January 20, 2020)

Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate Cancer
(Pending Submission as of January 24, 2020)

Niraparib (Zejula) for Ovarian Cancer
(Pending Submission as of January 10, 2020)

Find a Drug Review